Top Promising Stocks To Invest In 2015

Top Promising Stocks To Invest In 2015: Ab bVie Inc (ABBV)

AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products.

AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Advisors' Opinion:

• [By Ben Levisohn]

  AbbVie (ABBV) released solid financial results today, but Gilead Sciences (GILD) seems to be getting the benefit today.

  AbbVie reported a profit of 71 cents a share, beating forecasts for 68 cents, on sales of $4.56 billion, topping the Street consensus of $4.56 billion.

  On it’s conference call, AbbVie signaled that it didn’t intend to get into a hepatitis-C treatment pricing war. UBS analyst Matthew Roden says that’s good news for Gilead Sciences:

  AbbVie’s 1Q call just ended, on which it reiterated that pricing is “NOT our strategy” in HCV. Our HCV thesis on pricing has been that AbbVie will list price at parity, and that initial discounting would be limited between two players. We do expect that gross-net will widen over time with additional market entrants, but we do not expect significant price erosion in the near to mid-term. Secondly, we’ve modelled the HCV as a long-lived market, peaking globally at $26bn in 2022. AbbVie also expects a “cadence” of treatment to draw out the market over th! e long term. In our view, AbbVie’s stance is consistent with our constructive view on HCV, and specifically addresses investor pushback on [Gilead Sciences].

  Shares of AbbVie are little changed at $49.30 at 2:03 p.m., while Gilead Sciences has gained 0.7% to $74.60. Gilead’s gain is particularly impressive considering that the iShares Nasdaq Biotechnology ETF (IBB) has dropped 2.1% to $224.88 today.

• [By Keith Speights]

  This latest news confirms the view that Gilead has the pole position in the hep C race. AbbVie (NYSE: ABBV  ) claimed a victory last fall with a study showing that its four-drug regimen achieved a 99% cure rate after 12 weeks. Gilead's results included one arm of the study where patients were free of hep C after taking its drug combo after only eight weeks (and it did so with only three drugs at most, compared to AbbVie's four).

• [By Brian Orelli]

  That's true of rheumatoid arthritis, which has multiple blockbuster drugs serving patients. Pfizer's hoping that its oral medication, Xeljanz, can take down the current offerings, including Johnson & Johnson's Remicade, AbbVie's (NYSE: ABBV  ) Humira, and Enbrel, sold by Pfizer and Amgen (NASDAQ: AMGN  ) , which all have to be injected. It'll take awhile to capture sales from drugs that doctors are comfortable prescribing, but investors will be happy with just a fraction of the market -- Remicade topped $6 billion last year, Enbrel broke $4 billion, and Humira topped the list at $9.3 billion.

• [By Brian Orelli]

  Competition coming
  AbbVie (NYSE: ABBV  ) has its own interferon-free cocktail under review by the FDA. Assuming it gets approved later this year, we should see an interesting battle for patients. Harvoni is easier to take since it's just one pill per day, and doctors are familiar with Sovaldi, which will help make the transition to Harvoni easy.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-promising-stocks-to-invest-in-2015.html